Literature DB >> 29344203

Mucin 1 promotes radioresistance in hepatocellular carcinoma cells through activation of JAK2/STAT3 signaling.

Feng-Tao Yi1, Qi-Ping Lu2.   

Abstract

Mucin 1 (MUC1) is aberrantly overexpressed in numerous human cancer types, including hepatocellular carcinoma (HCC) and contributes to chemoresistance of tumor cells. The aim of the present study was to evaluate the possible implication of MUC1 in radioresistance of HCC cells and the underlying mechanisms. It was demonstrated that MUC1 was significantly upregulated in HCC cells following irradiation exposure, which was coupled with increased phosphorylation of signal transducer and activator of transcription 3 (STAT3). Enforced expression of MUC1 significantly (P<0.05) promoted the clonogenic survival of HCC cells following irradiation compared with empty vector-transfected cells. MUC1 overexpression resulted in >60% reduction in apoptosis induced by irradiation, as determined by Annexin-V/propidium iodide double staining and flow cytometry analysis. Furthermore, overexpression of MUC1 significantly (P<0.05) attenuated the activation of caspase-3 and poly (ADP-ribose) polymerase in response to irradiation exposure. Mechanistically, MUC1 inhibited irradiation-induced apoptosis through activation of janus kinase 2 (JAK2) and STAT3, and induction of anti-apoptotic proteins induced myeloid leukemia cell differentiation protein Mcl-1 (Mcl-1) and BCL2 like 1 (Bcl-xL). Small hairpin RNA-mediated knockdown of STAT3 or MUC1 resensitized MUC1-overexpressing cells to irradiation-induced apoptosis, which was accompanied by reduced expression of Bcl-xL and Mcl-1. Collectively, MUC1 contributes to radioresistance of HCC cells likely through activation of the JAK2/STAT3 signaling pathway and thus represents a potential target for improving radiotherapy against HCC.

Entities:  

Keywords:  Mucin 1; apoptosis; hepatocellular carcinoma; radioresistance; signal transducer and activator of transcription 3 signaling

Year:  2017        PMID: 29344203      PMCID: PMC5755255          DOI: 10.3892/ol.2017.7119

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  27 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways.

Authors:  Solange Tréhoux; Bélinda Duchêne; Nicolas Jonckheere; Isabelle Van Seuningen
Journal:  Biochem Biophys Res Commun       Date:  2014-12-13       Impact factor: 3.575

3.  MUC1 activates JNK1 and inhibits apoptosis under genotoxic stress.

Authors:  Qiongqiong Chen; Decai Li; Jian Ren; Chenghua Li; Zhi-Xiong Xiao
Journal:  Biochem Biophys Res Commun       Date:  2013-09-18       Impact factor: 3.575

4.  HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells.

Authors:  Dae-Hee Lee; Ki Sa Sung; David L Bartlett; Yong Tae Kwon; Yong J Lee
Journal:  Cell Signal       Date:  2014-11-18       Impact factor: 4.315

Review 5.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

6.  Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3.

Authors:  Chao-Yuan Huang; Chen-Si Lin; Wei-Tien Tai; Chi-Ying Hsieh; Chung-Wai Shiau; Ann-Lii Cheng; Kuen-Feng Chen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-03-06       Impact factor: 7.038

7.  The MUC1 mucin regulates the tumorigenic properties of human esophageal adenocarcinomatous cells.

Authors:  Caroline Gronnier; Emilie Bruyère; Fatima Lahdaoui; Nicolas Jonckheere; Michaël Perrais; Emmanuelle Leteurtre; Guillaume Piessen; Christophe Mariette; Isabelle Van Seuningen
Journal:  Biochim Biophys Acta       Date:  2014-07-06

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  A novel miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular carcinoma.

Authors:  Bo Zhou; Hongxu Chen; Dong Wei; Yi Kuang; Xiaobiao Zhao; Guangyao Li; Jun Xie; Ping Chen
Journal:  J Exp Clin Cancer Res       Date:  2014-06-30

10.  MUC1 extracellular domain confers resistance of epithelial cancer cells to anoikis.

Authors:  Q Zhao; T Piyush; C Chen; M A Hollingsworth; J Hilkens; J M Rhodes; L-G Yu
Journal:  Cell Death Dis       Date:  2014-10-02       Impact factor: 8.469

View more
  9 in total

1.  MUC1 is responsible for the pro-metastatic potential of calycosin in pancreatic ductal adenocarcinoma.

Authors:  Wenqing Chen; Zhu Zhang; Ken Kin-Lam Yung; Joshua Ka-Shun Ko
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

2.  Alpelisib and radiotherapy treatment enhances Alisertib-mediated cervical cancer tumor killing.

Authors:  Yaman Tayyar; Adi Idris; Josif Vidimce; Danyelle Assis Ferreira; Nigel Aj McMillan
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

Review 3.  Alpha-Fetoprotein Binding Mucin and Scavenger Receptors: An Available Bio-Target for Treating Cancer.

Authors:  Bo Lin; Qiujiao Wang; Kun Liu; Xu Dong; Mingyue Zhu; Mengsen Li
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

4.  MUC1 confers radioresistance in head and neck squamous cell carcinoma (HNSCC) cells.

Authors:  Tian-Qiao Huang; Ya-Nan Bi; Zheng Cui; Jin-Ping Guan; Yi-Chuan Huang
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

5.  Mucin 21 confers resistance to apoptosis in an O-glycosylation-dependent manner.

Authors:  Yuan Tian; Kaori Denda-Nagai; Tatsuya Tsukui; Katrin B Ishii-Schrade; Kyoko Okada; Yoshihiro Nishizono; Kosuke Matsuzaki; Margarete Hafley; Robert S Bresalier; Tatsuro Irimura
Journal:  Cell Death Discov       Date:  2022-04-11

Review 6.  Advances in MUC1-Mediated Breast Cancer Immunotherapy.

Authors:  Zhifeng Li; Dazhuang Yang; Ting Guo; Mei Lin
Journal:  Biomolecules       Date:  2022-07-06

Review 7.  MUC1: Structure, Function, and Clinic Application in Epithelial Cancers.

Authors:  Wenqing Chen; Zhu Zhang; Shiqing Zhang; Peili Zhu; Joshua Ka-Shun Ko; Ken Kin-Lam Yung
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

Review 8.  Radiation Resistance: A Matter of Transcription Factors.

Authors:  Chiara Galeaz; Cristina Totis; Alessandra Bisio
Journal:  Front Oncol       Date:  2021-06-01       Impact factor: 6.244

Review 9.  MUC1 is an oncoprotein with a significant role in apoptosis (Review).

Authors:  Katarzyna Supruniuk; Iwona Radziejewska
Journal:  Int J Oncol       Date:  2021-07-19       Impact factor: 5.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.